Combined immunotherapy could help control melanoma that has spread to the brain

June 5, 2017, Cancer Research UK
Combined immunotherapy could help control melanoma that has spread to the brain

A combination of two immunotherapy drugs is safe to give to patients with melanoma, a type of skin cancer, that has spread to the brain, and could help control the disease.

Melanomas that had spread to the brain responded to, or were kept stable, by the drugs ipilimumab (Yervoy) and nivolumab (Opdivo) in around half of patients, according to an early look at unpublished results from two clinical studies.

While patient numbers were small, the results could offer a new option if confirmed in future studies.

Dr Lynn Mara Schuchter, from the University of Pennsylvania in the US, said the findings 'could be practice changing'. But she added that patients now need to be followed up for longer.

Schuchter said that larger clinical trials would be needed to confirm the potential benefit for these patients, and to work out when is the best time to offer this treatment.

The findings were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in the US.

Little is known about how might be able to help control melanoma that has spread to the brain, a common complication in patients diagnosed with late stage disease.

Patients whose disease has spread to the brain have been ineligible for previous of immunotherapy for melanoma.

The phase 2 CheckMate 204 study , led by Dr Hussein Abdul-Hassan Tawbi from the University of Texas MD Anderson Cancer Center, and the phase 2 Anti-PD1 Brain Collaboration (ABC) trial , led by Professor Georgina Long from the University of Sydney, specifically recruited patients with melanoma that had spread to the brain. Most of these patients weren't experiencing symptoms as a result of the tumours in their brains.

Of the 75 patients treated on the CheckMate 204 study, 60 percent saw the disease in their brain respond to the combined treatment, or be kept stable by it, at the middle point of follow-up, which was 9.2 months.

16 patients (21 percent) saw the disease in their brain completely disappear following treatment.

Professor Peter Johnson, Cancer Research UK's chief clinician, said the results of the CheckMate 2014 study "suggest that a combination of the immunotherapy drugs nivolumab and ipilimumab is safe and effective against that's spread to the brain."

"Radiotherapy can have limited benefits, so these results are encouraging and may be another option for some patients in the future once larger trials are done," he added.

On the ABC trial, 42 percent of the 26 patients treated saw the disease in their brain respond to some degree to the combined immunotherapy drugs at the middle point of follow-up, which was 16.4 months after treatment. This increased to 50 percent when looking at 20 patients who had not previously been treated with a targeted cancer drug for melanoma, suggesting the immunotherapy combination may work better upfront, although these numbers are small.

4 patients (15 percent) saw the disease in their completely disappear following the combined immunotherapy treatment.

Six months after treatment, 67 percent of patients on the CheckMate 204 study hadn't seen their disease get worse, so-called progression free survival. On the ABC trial this was 46 percent.

Schuchter said that while these early results were 'fantastic', most patients on these studies did ultimately see their get worse. And across the different study groups between a quarter and half of patients who took part have died.

According to both lead researchers and Schuchter, the side effects experienced by on these studies were as expected for immunotherapy treatment of . But in some cases these can be serious, and must be carefully managed.

Explore further: Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

More information: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. abstracts.asco.org/199/AbstView_199_181375.html

A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). abstracts.asco.org/199/AbstView_199_187928.html

Related Stories

Some head and neck cancer patients benefit from continued checkpoint inhibitor treatment

April 3, 2017
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer ...

New immunotherapy combination shows promise for patients with advanced melanoma

April 5, 2017
Treatment with a combination of ipilimumab (Yervoy) and Coxsackievirus A21 (CVA21; Cavatak) led to durable responses in a number of patients with advanced melanoma, including some whose melanoma had progressed despite prior ...

Adding the IDO-pathway inhibitor indoximod to pembrolizumab improved the melanoma response rate

April 5, 2017
Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously ...

Two-drug immunotherapy deemed safe for lung cancer patients, study shows

June 2, 2016
Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that ...

Surgery may be best for advanced melanoma

April 5, 2017
(HealthDay)—Surgery to remove melanoma—the deadliest form of skin cancer—can extend the lives of patients whose disease has spread to the abdomen area, new research suggests.

Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

September 21, 2016
Brain metastases are one of the most common complications of advanced melanoma, requiring multidisciplinary management. Patients who are diagnosed with these metastases have an expected median survival of only 4 to 5 months. ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.